GTX-102 ( DrugBank: GTX-102 )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
65	原発性免疫不全症候群	1
201	アンジェルマン症候群	1

65. 原発性免疫不全症候群

臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05531890 (ClinicalTrials.gov)	September 13, 2022	31/8/2022	Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjec ...	Crossover Study to Evaluate the Comparative Bioavailability, Pharmacokinetics, and Safety of GTX-102 ...	Ataxia Telangiectasia	Drug: GTX-102medium dose fast Period 1 and Period 2;Drug: GTX-102medium dose slow Period 1 and Perio ...	Acasti Pharma Inc.	NULL	Active, not recruiting	18 Years	55 Years	All	48	Phase 1	Canada

臨床試験数 : 25 / 薬物数 : 40 - (DrugBank : 11) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 20

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04259281 (ClinicalTrials.gov)	February 24, 2020	31/1/2020	A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome	A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability ...	Angelman Syndrome	Drug: GTX-102	Ultragenyx Pharmaceutical Inc	NULL	Recruiting	4 Years	17 Years	All	83	Phase 1/Phase 2	United States;Canada;United Kingdom